Cipher Pharmaceuticals (TSE:CPH) PT Set at C$12.50 by Canaccord Genuity Group

Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR received a C$12.50 price objective from analysts at Canaccord Genuity Group in a report issued on Monday, Marketbeat Ratings reports. The firm currently has a "hold" rating on the stock. Canaccord Genuity Group's target price would indicate a potential upside of 13.22% from the stock's previous close.

Cipher Pharmaceuticals Stock Performance

Shares of CPH traded down C$0.05 on Monday, reaching C$11.04. 17,173 shares of the stock traded hands, compared to its average volume of 36,537. The firm has a market cap of C$198.20 million, a price-to-earnings ratio of 12.19 and a beta of 1.20. Cipher Pharmaceuticals has a 12 month low of C$8.01 and a 12 month high of C$19.69. The stock's 50-day moving average price is C$12.31 and its 200-day moving average price is C$13.98. The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67.

Insider Activity at Cipher Pharmaceuticals

In other news, Director Harold Morton Wolkin sold 3,500 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of C$13.49, for a total value of C$47,215.00. 42.00% of the stock is currently owned by insiders.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.